The new online face of BIOHIT

May 24, 2022

The launch of the new website coincides with an exciting time for BIOHIT, as the company moves to fulfil its vision of becoming a leading voice in digestive disease diagnosis, to empower healthcare providers and improve the lives of patients. The company’s strong portfolio has been created to address previously unmet needs of healthcare professionals working in this field, and enables the early diagnosis and prevention of gastrointestinal diseases. This range includes:

GastroPanel^® – a simple blood test that aids gastric cancer risk stratification
Therapeutic drug monitoring (TDM) – for chronic inflammatory diseases
Peptest^®– for non-invasive diagnosis of reflux
GA-map^® Dysbiosis Test Lx – a straightforward lab-based test for identifying and characterising dysbiosis using faecal samples
IDK^®Faecal Bile Acids – a simple colorimetric assay to help diagnose bile acid diarrhoea

Graham Johnson, Managing Director of BIOHIT, said: “We are excited to showcase the fresh new look of our website, and look forward to welcoming many more online guests in the coming weeks and months. This update will make it far easier for our visitors to locate exactly what they need and learn about the crucial work that we do here at BIOHIT.”

For more information about BIOHIT product lines, browse www.biohithealthcare.co.uk.

About BIOHIT HealthCare

BIOHIT HealthCare is a Finnish biotech company, headquartered in Helsinki, that specialises in the development, manufacture and distribution of kits and assays for the screening, diagnosis and monitoring of digestive diseases. Its core disease focus areas include stomach health and dyspepsia, reflux and acid dysregulation, Inflammatory Bowel Disease (IBD), functional gastrointestinal disorders (FGID), Irritable bowel syndrome (IBS), and gut microbiota dysbiosis. Innovating for Health www.biohithealthcare.co.uk